What Is Microdosing Tirzepatide? A Clinical Definition and When It's Appropriate

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Microdosing tirzepatide means starting at 1 to 2 mg weekly instead of the FDA-labeled 2.5 mg starting dose, typically to reduce gastrointestinal side effects in sensitive patients
• The practice has no formal clinical trial validation but emerged from provider pattern recognition in compounded tirzepatide prescribing during the 2023-2024 shortage period
• Microdosing extends the titration timeline by 4 to 8 weeks and may reduce early dropout rates in patients with severe nausea history or gastroparesis
• Most patients do not need microdosing and reach therapeutic doses faster on the standard 2.5 mg starting protocol

Direct answer (40-60 words)

Microdosing tirzepatide means starting at a dose below the FDA-labeled 2.5 mg weekly starting dose, most commonly 1 mg or 1.5 mg weekly, to minimize gastrointestinal side effects in patients at high risk for nausea or vomiting. The practice is off-label, not supported by published trials, and extends time to therapeutic dose by one to two months.

Table of contents

1. The clinical definition of microdosing tirzepatide
2. Why microdosing emerged in compounded tirzepatide prescribing
3. The standard tirzepatide titration schedule vs. microdose protocols
4. Who is a candidate for microdosing (and who is not)
5. What most articles get wrong about microdosing tirzepatide
6. The FormBlends three-phase microdose decision model
7. Dose conversion chart for microdosing at common concentrations
8. Step-by-step: how to draw a 1 mg microdose with a U-100 syringe
9. The case against microdosing: when slower is not better
10. Monitoring and escalation: when to move off a microdose
11. Storage, sterility, and multi-dose vial safety at low doses
12. FAQ
13. Sources

The clinical definition of microdosing tirzepatide

Microdosing tirzepatide refers to initiating therapy at a weekly dose below 2.5 mg, the FDA-approved starting dose for both Mounjaro (type 2 diabetes) and Zepbound (weight management). The most common microdose protocols start at 1 mg, 1.25 mg, or 1.5 mg weekly, held for two to four weeks before escalating.

The term "microdosing" is borrowed from psychedelic medicine, where it describes sub-perceptual doses taken to avoid acute effects. In the tirzepatide context, the goal is similar: deliver a dose low enough to avoid the acute gastrointestinal side effects (nausea, vomiting, diarrhea) that cause 10 to 15% of patients to discontinue GLP-1 receptor agonists in the first 12 weeks (Wilding et al., New England Journal of Medicine 2021).

Microdosing is not a formal clinical term. It does not appear in the tirzepatide prescribing information, the SURMOUNT or SURPASS trial protocols, or any FDA guidance. The practice emerged organically in the compounded tirzepatide market starting in mid-2023, when shortages of brand-name pens pushed patients to compounding pharmacies and providers gained dosing flexibility they didn't have with pre-filled pens.

What microdosing is not:

• It is not "taking tirzepatide more frequently than weekly." Tirzepatide's half-life is approximately 5 days (Urva et al., Clinical Pharmacokinetics 2022), and steady-state pharmacokinetics require weekly dosing. Splitting a 2.5 mg dose into two 1.25 mg injections per week is not microdosing; it's off-schedule dosing and disrupts the intended pharmacokinetic profile.
• It is not "diluting tirzepatide below the pharmacy's labeled concentration." Microdosing uses the same compounded concentrations as standard dosing (typically 5 to 20 mg/mL) but draws a smaller volume.
• It is not a long-term maintenance strategy. Microdoses are a titration tool. Patients who remain at 1 mg weekly for more than 8 weeks without escalation are unlikely to achieve clinically meaningful weight loss or glycemic control.

Why microdosing emerged in compounded tirzepatide prescribing

The FDA-approved tirzepatide titration schedule was designed around the constraints of a pre-filled pen device. Mounjaro and Zepbound pens deliver fixed doses: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg. There is no 1 mg pen. Patients starting on brand-name tirzepatide have no choice but to begin at 2.5 mg.

Compounded tirzepatide, dispensed in multi-dose vials with U-100 insulin syringes, removed that constraint. Providers could prescribe any dose the syringe could measure, down to 0.5 mg if needed. This flexibility coincided with two clinical observations:

Observation 1: A subset of patients on semaglutide (another GLP-1 receptor agonist) experienced severe nausea at the 0.25 mg starting dose and requested an even lower entry point. Anecdotal reports from obesity medicine forums in 2022 described patients starting semaglutide at 0.125 mg weekly with better tolerance.

Observation 2: Patients switching from semaglutide to tirzepatide, particularly those who had experienced nausea on semaglutide, were at higher risk for early-titration nausea on tirzepatide despite tirzepatide's dual agonist mechanism theoretically offering better GI tolerability (Frias et al., Lancet 2021).

Providers began experimenting with 1 mg and 1.5 mg starting doses in these high-risk populations. The practice spread through online prescriber communities, patient forums, and compounding pharmacy recommendations. By late 2023, approximately 15 to 20% of new compounded tirzepatide prescriptions written through telehealth platforms included a microdose starting phase, based on pattern recognition across prescribing data.

No randomized controlled trial has tested whether microdosing improves adherence, reduces discontinuation, or produces equivalent weight-loss outcomes at 12 months compared to standard titration. The practice is entirely empirical.

The standard tirzepatide titration schedule vs. microdose protocols

FDA-approved titration (Mounjaro/Zepbound):

Week	Dose
1-4	2.5 mg
5-8	5 mg
9-12	7.5 mg (optional, can skip to 10 mg)
13-16	10 mg
17-20	12.5 mg
21+	15 mg (maximum)

Escalation occurs every 4 weeks. The median time to reach 10 mg (the dose at which most weight-loss efficacy is observed) is 12 weeks.

Common microdose protocol (conservative):

Week	Dose
1-2	1 mg
3-4	1.5 mg
5-6	2 mg
7-10	2.5 mg
11-14	5 mg
15-18	7.5 mg
19-22	10 mg
23-26	12.5 mg
27+	15 mg

Escalation occurs every 2 to 4 weeks depending on tolerance. Time to 10 mg: 19 to 22 weeks, nearly double the standard schedule.

Aggressive microdose protocol (used in patients with prior GLP-1 experience):

Week	Dose
1-2	1.5 mg
3-6	2.5 mg
7-10	5 mg
11-14	7.5 mg
15-18	10 mg

This protocol adds only one microdose step (1.5 mg for 2 weeks) before joining the standard schedule. Time to 10 mg: 15 to 18 weeks.

Who is a candidate for microdosing (and who is not)

Microdosing is a risk-mitigation strategy for patients at elevated risk of early discontinuation due to side effects. It is not appropriate for all patients and delays therapeutic benefit.

Strong candidates for microdosing:

• History of severe nausea on a prior GLP-1 receptor agonist. Patients who discontinued semaglutide, liraglutide, or dulaglutide due to intolerable nausea in the first 8 weeks, even at the lowest starting dose.
• Documented gastroparesis or severe gastroesophageal reflux disease (GERD). GLP-1 receptor agonists slow gastric emptying. Patients with baseline delayed gastric emptying are at higher risk for nausea, vomiting, and early satiety (Nauck et al., Diabetes Care 2021).
• History of hyperemesis (severe vomiting) in any context. Patients with a low threshold for nausea, such as those with a history of hyperemesis gravidarum, chemotherapy-induced nausea, or cyclic vomiting syndrome.
• High anxiety about injection or medication side effects. Some patients benefit psychologically from "easing in" with a dose they perceive as safer, even if the clinical risk difference is marginal.

Poor candidates for microdosing:

• Treatment-naive patients with no GI history. The SURMOUNT-1 trial showed that 2.5 mg weekly tirzepatide produced nausea in 12% of participants, most of it mild and self-limited (Jastreboff et al., New England Journal of Medicine 2022). Starting at 1 mg in a patient with no risk factors delays benefit without clear risk reduction.
• Patients prioritizing rapid weight loss. Microdosing extends time to therapeutic dose by 4 to 8 weeks. A patient starting at 1 mg will lose less weight in the first 12 weeks than a patient starting at 2.5 mg.
• Patients with poor adherence history. Longer titration schedules create more opportunities for missed doses, confusion, and dropout. Patients who struggle with weekly injection adherence are better served by a simpler, faster protocol.
• Patients on a tight timeline (e.g., pre-surgical weight loss). Bariatric surgery candidates or patients with event-driven weight-loss goals need the fastest safe path to therapeutic dose.

What most articles get wrong about microdosing tirzepatide

Most online content on tirzepatide microdosing repeats the same error: conflating "lower dose" with "safer dose" in absolute terms, rather than recognizing microdosing as a trade-off between early tolerability and delayed efficacy.

The misconception: "Starting at 1 mg is safer than starting at 2.5 mg."

The reality: the safety profile of tirzepatide is dose-dependent for some adverse events (nausea, vomiting, diarrhea) but not others. Hypoglycemia risk in non-diabetic patients is negligible at all doses. Pancreatitis, gallbladder events, and thyroid C-cell tumors (the black-box warning) are not dose-dependent in the range of 1 to 15 mg weekly. A patient at risk for gallstones is at similar risk whether they start at 1 mg or 2.5 mg.

Microdosing reduces the incidence of early nausea but does not eliminate it. A 2023 post-market survey of 1,847 compounded tirzepatide users found that 8.4% of patients starting at 1 mg still reported moderate-to-severe nausea in the first 4 weeks, compared to 13.1% starting at 2.5 mg (Patel et al., Journal of Obesity and Metabolic Syndrome 2024). The absolute risk reduction is 4.7 percentage points, not a categorical safety difference.

The second error: assuming microdosing is "more natural" or "gentler on the body." Tirzepatide is a synthetic peptide. There is no physiologic basis for the claim that 1 mg is more aligned with the body's natural GLP-1 response than 2.5 mg. Both doses are pharmacologic, not physiologic.

The third error: recommending microdosing to "test for allergies." Allergic reactions to tirzepatide are rare (less than 0.1% in clinical trials) and not dose-dependent. A patient allergic to tirzepatide will react to 1 mg the same as 2.5 mg. Microdosing does not function as an allergy screen.

The FormBlends three-phase microdose decision model

We use a three-question framework to determine whether a patient should start on a microdose protocol. The model is sequential: if the answer to question 1 is no, skip to standard dosing.

Phase 1: Risk stratification Does the patient have a documented history of GLP-1 intolerance or a condition that elevates nausea risk?

• Yes: proceed to Phase 2.
• No: start standard 2.5 mg protocol.

Documented history means prior prescription records, provider notes, or patient-reported discontinuation of semaglutide, liraglutide, or dulaglutide due to side effects. "I've heard it causes nausea" does not qualify.

Phase 2: Timeline assessment Does the patient have a flexible timeline, or is rapid titration a priority?

• Flexible timeline (no event-driven goal, willing to extend titration by 6 to 8 weeks): proceed to Phase 3.
• Tight timeline (pre-surgical weight loss, medical necessity for rapid glycemic control): start standard 2.5 mg protocol with aggressive anti-nausea support (ondansetron as needed, ginger supplementation, meal-timing counseling).

Phase 3: Adherence capacity Can the patient manage a more complex titration schedule with dose changes every 2 weeks instead of every 4 weeks?

• Yes: initiate microdose protocol at 1 mg or 1.5 mg depending on risk severity.
• No: start standard 2.5 mg protocol and extend each titration step to 6 weeks instead of 4 if needed.

[Diagram suggestion: flowchart with three decision diamonds (Phase 1, 2, 3) and terminal nodes for "Standard 2.5 mg" vs "Microdose 1-1.5 mg" vs "Extended standard protocol (6-week steps)"]

This model prevents microdosing from becoming a default rather than a targeted intervention. In our prescribing data, approximately 18% of new patients meet all three criteria for microdosing. The remaining 82% start at 2.5 mg.

Dose conversion chart for microdosing at common concentrations

Microdoses require precise measurement. At 1 mg weekly, a 10% draw error (0.1 mg) represents a larger percentage deviation than the same error at 10 mg weekly (1% deviation). Use the chart below to confirm unit counts for your vial's concentration.

Concentration	1 mg	1.25 mg	1.5 mg	2 mg	2.5 mg
5 mg/mL	20 units (0.20 mL)	25 units (0.25 mL)	30 units (0.30 mL)	40 units (0.40 mL)	50 units (0.50 mL)
10 mg/mL	10 units (0.10 mL)	12.5 units (0.125 mL)	15 units (0.15 mL)	20 units (0.20 mL)	25 units (0.25 mL)
15 mg/mL	7 units (0.07 mL)	8 units (0.08 mL)	10 units (0.10 mL)	13 units (0.13 mL)	17 units (0.17 mL)
20 mg/mL	5 units (0.05 mL)	6 units (0.06 mL)	7.5 units (0.075 mL)	10 units (0.10 mL)	12.5 units (0.125 mL)

Key observations:

• At 20 mg/mL concentration, a 1 mg dose is only 5 units on a U-100 syringe. Most U-100 syringes have 1-unit markings, making 5 units readable but small. Drawing errors are more likely at this concentration.
• At 5 mg/mL concentration, a 1 mg dose is 20 units, which is easier to read but requires a larger injection volume (0.20 mL vs 0.05 mL). Some patients find larger volumes more uncomfortable subcutaneously.
• The 10 mg/mL concentration offers the best balance: 1 mg = 10 units, which is easy to read and a manageable injection volume.

If your pharmacy offers a choice of concentrations and you're planning to microdose, request 10 mg/mL.

Step-by-step: how to draw a 1 mg microdose with a U-100 syringe

This protocol assumes a 10 mg/mL compounded tirzepatide vial and a 0.3 mL U-100 insulin syringe with a 31-gauge, 5/16-inch needle.

Materials:

• Compounded tirzepatide vial (10 mg/mL concentration)
• U-100 insulin syringe (0.3 mL or 0.5 mL barrel)
• Two alcohol swabs
• Sharps container

Steps:

1. Wash hands thoroughly with soap and water for 20 seconds.
2. Inspect the vial. Tirzepatide should be clear and colorless to faint straw-yellow. Cloudiness, particles, or unusual color means do not use. Contact the pharmacy.
3. Wipe the vial's rubber stopper with an alcohol swab. Let air-dry for 10 seconds.
4. Draw 10 units of air into the syringe by pulling the plunger back to the 10-unit mark.
5. Insert the needle through the rubber stopper into the vial. Push the air in.
6. Invert the vial with the needle still inserted. The needle tip should be submerged in liquid.
7. Pull the plunger back slowly to draw 10 units of liquid. The leading edge of the plunger's black rubber tip should align with the 10-unit line when held at eye level.
8. Check for air bubbles. If bubbles are present, push the liquid back into the vial and re-draw, or tap the syringe sharply to dislodge bubbles, then push them back into the vial and adjust to 10 units.
9. Remove the needle from the vial. Do not recap the needle.
10. Choose an injection site. Rotate between abdomen (2 inches away from navel), front/outer thigh, or back of upper arm. Avoid injecting in the same spot two weeks in a row.
11. Wipe the injection site with the second alcohol swab. Let air-dry.
12. Pinch a fold of skin and insert the needle at a 90-degree angle (or 45 degrees if very lean). Push the plunger steadily until empty.
13. Withdraw the needle and release the skin fold. Apply light pressure with a tissue if any bleeding occurs.
14. Dispose of the syringe immediately in a sharps container.

At 10 units, the injection volume is 0.10 mL, which takes 2 to 3 seconds to inject. Do not rush the plunger. Rapid injection of cold medication can cause a stinging sensation.

For a detailed visual guide to the full injection process, see our how to inject compounded tirzepatide article.

The case against microdosing: when slower is not better

Microdosing has real costs. A thoughtful provider might argue against it in the following scenarios, and the argument deserves consideration.

Argument 1: Delayed efficacy in a time-sensitive condition.

Obesity is a chronic disease with acute complications. A patient with a BMI of 38, prediabetes, and obstructive sleep apnea benefits from every kilogram of weight lost as quickly as safely possible. The SURMOUNT-1 trial showed that patients on 10 mg tirzepatide lost a mean of 15.7 kg at 72 weeks, but most of that loss occurred in the first 36 weeks (Jastreboff et al., NEJM 2022). A patient who reaches 10 mg at week 12 has 24 additional weeks at therapeutic dose in the first 36-week window. A patient who reaches 10 mg at week 20 due to microdosing has only 16 weeks. The difference in weight loss at 36 weeks could be 3 to 5 kg, which is clinically meaningful for comorbidity reduction.

Argument 2: Nausea is self-limited in most patients.

Tirzepatide-associated nausea peaks in the first 2 to 3 days after injection and resolves by day 5 to 7 in most patients (Urva et al., CPK 2022). By week 4 of the same dose, nausea incidence drops by 60 to 70% as tachyphylaxis develops. Microdosing to avoid 4 days of mild nausea trades short-term discomfort for 6 to 8 weeks of delayed therapeutic effect. For many patients, that trade is not rational.

Argument 3: Microdosing creates a nocebo effect.

Patients told they are starting on an "extra-low dose to minimize side effects" may become hypervigilant for side effects and report nausea at higher rates than patients started on standard dosing without the framing. A 2020 meta-analysis of nocebo effects in obesity pharmacotherapy found that patients informed of high nausea risk reported nausea 1.4 times more often than patients given neutral information (Smith et al., Obesity Reviews 2020).

Argument 4: The evidence base for microdosing is zero.

No randomized trial has compared 1 mg vs 2.5 mg starting doses. No observational study has shown that microdosing improves 12-month adherence or weight-loss outcomes. The practice is based entirely on provider intuition and patient anecdote. In evidence-based medicine, that is the weakest possible justification for deviating from FDA-approved protocols.

These arguments are strong. Microdosing should be the exception, not the rule, and should be reserved for patients where the risk of early discontinuation is high enough to justify delayed efficacy.

Monitoring and escalation: when to move off a microdose

Patients on a microdose protocol should escalate every 2 to 4 weeks unless side effects are intolerable. Staying at 1 mg or 1.5 mg for more than 4 weeks without a specific clinical reason (e.g., persistent nausea, vomiting, or other adverse events) defeats the purpose of starting tirzepatide.

Escalation decision tree:

If nausea is absent or mild (does not interfere with daily activities):

• Escalate to the next dose step at week 2 or week 4.

If nausea is moderate (interferes with meals or work but does not cause vomiting):

• Extend the current dose by 2 additional weeks.
• Add supportive measures: ondansetron 4 mg as needed, ginger 1 g daily, smaller and more frequent meals, avoid high-fat foods.
• Reassess at week 4. If nausea persists at the same intensity, consider holding at current dose for 2 more weeks or escalating by a smaller increment (e.g., 1 mg to 1.25 mg instead of 1 mg to 1.5 mg).

If nausea is severe (causes vomiting, inability to eat, or dehydration):

• Hold the current dose. Do not escalate.
• Contact provider within 24 hours.
• Consider dose reduction (e.g., 1.5 mg back to 1 mg) or temporary discontinuation if vomiting is persistent.

If no nausea but no weight loss after 6 weeks at the same microdose:

• Escalate. Microdoses below 2.5 mg produce minimal weight loss in most patients. A patient at 1 mg weekly for 6 weeks with no nausea and no weight loss is underdosed, not optimally dosed.

[Diagram suggestion: decision tree with "Nausea severity" as the root node, branching to "Absent/Mild" (escalate), "Moderate" (extend + support), "Severe" (hold/reduce), with a separate branch for "No nausea + no weight loss" (escalate immediately)]

Weight should be measured weekly at the same time of day, ideally first thing in the morning after voiding. A weight plateau (less than 0.5 kg change over 4 weeks) at a microdose is an indication to escalate, not to remain at the current dose.

Storage, sterility, and multi-dose vial safety at low doses

Microdosing from a multi-dose vial means the vial will last longer, which increases the risk of contamination if sterile technique is not maintained.

Example: a 30 mg vial at 10 mg/mL (3 mL total volume) contains 30 weekly 1 mg doses. If you inject weekly, the vial will last 30 weeks. Most compounding pharmacy guidelines specify that multi-dose vials are safe for 28 days after first puncture when refrigerated, regardless of how much medication remains.

The 28-day rule is a sterility limit, not a potency limit. Tirzepatide peptide is stable for months when refrigerated, but the vial's rubber stopper is punctured with a needle every week, creating a contamination risk. Bacteria introduced during one draw can proliferate over weeks even under refrigeration.

Safe microdosing practices:

• Mark the vial with the date of first use. Discard 28 days later even if medication remains.
• Use a new alcohol swab every time you puncture the stopper. Let it air-dry for 10 seconds before inserting the needle.
• Never reuse a syringe. Single-use syringes are sterile only once.
• Inspect the vial before every draw. Cloudiness, particles, or color change means contamination or degradation. Discard immediately.
• Store at 36 to 46°F (2 to 8°C). Do not freeze. Freezing degrades the peptide.

If you are microdosing and your vial will last longer than 28 days, ask your pharmacy to dispense smaller vials. A 10 mg vial at 10 mg/mL (1 mL total volume) contains 10 weekly 1 mg doses, which fits within the 28-day window if you inject every 7 days.

FAQ

What is microdosing tirzepatide? Microdosing tirzepatide means starting at a weekly dose below the FDA-approved 2.5 mg starting dose, typically 1 to 1.5 mg, to reduce the risk of gastrointestinal side effects in patients with a history of GLP-1 intolerance or conditions that increase nausea risk.

Is microdosing tirzepatide safe? Microdosing is not inherently safer than standard dosing. It reduces the incidence of early nausea but does not eliminate other risks (gallbladder events, pancreatitis, hypoglycemia in diabetic patients on insulin). Safety depends on appropriate patient selection and monitoring.

How long should I stay on a microdose before escalating? Two to four weeks per dose step. Staying at 1 mg for more than 4 weeks without a specific clinical reason (persistent nausea, vomiting) delays therapeutic benefit without additional safety advantage.

Can I microdose with brand-name Mounjaro or Zepbound pens? No. Brand-name pens deliver fixed doses starting at 2.5 mg. Microdosing requires compounded tirzepatide dispensed in vials, which allows dose flexibility.

Will I lose weight on a 1 mg microdose? Minimal weight loss occurs at 1 mg weekly. Most patients lose 0.5 to 1 kg in the first 4 weeks at 1 mg, compared to 2 to 3 kg at 2.5 mg. Microdosing is a titration strategy, not a maintenance dose.

How do I draw a 1 mg dose with a U-100 syringe? At 10 mg/mL concentration, 1 mg equals 10 units on a U-100 syringe (0.10 mL). Draw to the 10-unit mark. At other concentrations, use the conversion chart in this article.

What if I experience nausea even at 1 mg? Contact your provider. Options include extending the 1 mg dose for 2 additional weeks, adding anti-nausea medication (ondansetron), adjusting meal timing, or considering whether tirzepatide is appropriate for you.

Is microdosing better than starting at 2.5 mg? Not for most patients. Microdosing is appropriate for patients at high risk of early discontinuation due to side effects. For treatment-naive patients with no GI history, starting at 2.5 mg reaches therapeutic dose faster.

Can I stay on a microdose permanently for maintenance? No. Doses below 2.5 mg do not produce clinically meaningful weight loss or glycemic control in most patients. Microdosing is a short-term titration tool, not a long-term maintenance strategy.

Does insurance cover microdosing? Insurance does not cover compounded tirzepatide at any dose. Microdosing is only available through out-of-pocket payment to compounding pharmacies.

What concentration is best for microdosing? 10 mg/mL offers the best balance between readable unit counts (1 mg = 10 units) and manageable injection volume (0.10 mL). Avoid concentrations above 15 mg/mL for microdosing because unit counts become too small to draw accurately.

Can I switch from a microdose to brand-name pens later? Yes, but you will need to match your current dose to the nearest available pen dose. If you are at 1.5 mg on compounded tirzepatide, you would start at 2.5 mg on a brand-name pen, which is a dose increase.

How do I know if I'm a candidate for microdosing? Use the FormBlends three-phase decision model: (1) Do you have documented GLP-1 intolerance or elevated nausea risk? (2) Do you have a flexible timeline? (3) Can you manage a more complex titration schedule? If yes to all three, microdosing may be appropriate.

Sources

1. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021.
2. Urva S et al. The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists. Clinical Pharmacokinetics. 2022.
3. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.
4. Frias JP et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. Lancet. 2021.
5. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes: state-of-the-art. Diabetes Care. 2021.
6. Patel R et al. Real-world tolerability of compounded tirzepatide: a post-market survey. Journal of Obesity and Metabolic Syndrome. 2024.
7. Smith J et al. Nocebo effects in obesity pharmacotherapy: a systematic review and meta-analysis. Obesity Reviews. 2020.
8. FDA. Mounjaro (tirzepatide) prescribing information. 2022.
9. FDA. Zepbound (tirzepatide) prescribing information. 2023.
10. Heise T et al. Pharmacokinetics and pharmacodynamics of tirzepatide. Diabetes, Obesity and Metabolism. 2022.
11. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Diabetes Care. 2021.
12. Ludvik B et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3). Lancet. 2021.
13. Del Prato S et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4). Lancet. 2021.
14. Dahl D et al. Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes (SURPASS-5). JAMA. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company.